Andere talen Atara Biotherapeutics, Inc.

Aandelen

ATRA

US0465131078

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,6917 ^USD	-3,25%		-2,96%	+34,89%

01/04	ATARA BIOTHERAPEUTICS, INC. : Stifel Nicolaus handhaaft het Neutraal advies	ZM
29/03	Eric Dobmeier stelt zich niet herkiesbaar als lid van de Raad van Bestuur van Atara Biotherapeutics, Inc.	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	05/04
Eric Dobmeier Not to Stand for Re-Election as Member of Board of Directors of Atara Biotherapeutics, Inc	29/03
Atara Biotherapeutics: Q4 Earnings Snapshot	28/03
Atara Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress	28/03
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q4 Revenue $4.3M	28/03
Atara Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03
North American Morning Briefing : Stocks Edge -2-	27/03
North American Morning Briefing : Markets on Hold -2-	20/03
North American Morning Briefing : Stock Futures -2-	13/03
Atara Says ATA3219 IND Application Approved by FDA for Lupus Nephritis CAR T-Cell Therapy	29/02
Atara Biotherapeutics Gets FDA Clearance for ATA3219 IND Application	29/02
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy	29/02
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference	28/02
Atara Biotherapeutics Submits New Drug Application to FDA for ATA3219 to Treat Lupus Nephritis	14/02
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis	14/02
Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis	14/02
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology	01/02
Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology	01/02
Latest Buzz on The Street: Noteworthy Developments at DYAI, ELEV, ATRA, ESPR, KAVL	17/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Atara Biotherapeutics, Inc.

Aandelen

ATRA

US0465131078

Andere talen

Filters